1. Home
  2. PLXS vs PCVX Comparison

PLXS vs PCVX Comparison

Compare PLXS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plexus Corp.

PLXS

Plexus Corp.

HOLD

Current Price

$216.74

Market Cap

7.2B

Sector

Technology

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$60.91

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLXS
PCVX
Founded
1979
2013
Country
United States
United States
Employees
20000
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
7.0B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
PLXS
PCVX
Price
$216.74
$60.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
★ $304.60
$117.30
AVG Volume (30 Days)
190.0K
★ 3.4M
Earning Date
10-28-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 56.11
N/A
EPS
★ 4.90
N/A
Revenue
N/A
★ N/A
Revenue This Year
$21.42
N/A
Revenue Next Year
$14.96
N/A
P/E Ratio
$45.27
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$132.03
$39.87
52 Week High
$307.06
$90.75

Technical Indicators

Market Signals
Indicator
PLXS
PCVX
Relative Strength Index (RSI) 27.48 45.93
Support Level $190.68 $52.91
Resistance Level $220.17 $62.00
Average True Range (ATR) 7.71 4.10
MACD -4.57 -0.68
Stochastic Oscillator 0.69 2.27

Price Performance

Historical Comparison
PLXS
PCVX

About PLXS Plexus Corp.

Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: